Kuller L H, Hulley S B, Cohen J D, Neaton J
Circulation. 1986 Jan;73(1):114-23. doi: 10.1161/01.cir.73.1.114.
The relationship between diuretic therapy and possible increased risk of coronary heart disease (CHD), especially sudden death, is controversial. The initial report from the Multiple Risk Factor Intervention Trial (MRFIT) raised the possibility that the increased CHD mortality observed in a subset of special intervention men with hypertension and certain electrocardiographic abnormalities on their baseline examination might be an unexpected adverse effect of diuretic therapy. Subsequent reports from the MRFIT have revealed a stronger association of CHD mortality to hydrochlorothiazide than to chlorthalidone. There was no consistent relationship of CHD mortality to the dose of either drug, to the most recent serum potassium level, or to the presence of ventricular premature beats. Unfavorable trends of the same magnitude were also seen among similar white men in the Hypertension Detection and Follow-up Program and in the Oslo hypertension trial, although the sample sizes in these two studies were too small to yield clearcut conclusions. Clinical studies have shown an increased risk of CHD death among hypertensive men with left ventricular hypertrophy. Such men are also noted to have a higher frequency of ventricular premature beats, even in the absence of diuretic therapy. Other studies have shown that diuretic-induced hypokalemia is accentuated in the presence of epinephrine and that low potassium levels decrease the threshold for ventricular fibrillation. Thus, although the evidence is still incomplete, it is possible that the excess CHD mortality among MRFIT special intervention men with electrocardiographic abnormalities may have been caused by a combination of increased left ventricular mass in the presence of coronary atherosclerosis, and hypokalemia caused by good compliance with diuretic therapy and accentuated by stress-induced increases in circulating catecholamines. Given the very large population of patients receiving diuretic therapy, further evaluation of this possibility is important.
利尿疗法与冠心病(CHD)风险可能增加,尤其是猝死之间的关系存在争议。多重危险因素干预试验(MRFIT)的初步报告提出,在基线检查时有高血压和某些心电图异常的特定干预男性亚组中观察到的冠心病死亡率增加,可能是利尿疗法意想不到的不良反应。MRFIT随后的报告显示,冠心病死亡率与氢氯噻嗪的关联比与氯噻酮更强。冠心病死亡率与这两种药物的剂量、最新血清钾水平或室性早搏的存在均无一致关系。在高血压检测与随访计划以及奥斯陆高血压试验中,类似的白人男性中也出现了同样程度的不利趋势,尽管这两项研究的样本量太小,无法得出明确结论。临床研究表明,左心室肥厚的高血压男性冠心病死亡风险增加。即使在没有利尿疗法的情况下,这些男性的室性早搏频率也较高。其他研究表明,在肾上腺素存在的情况下,利尿诱导的低钾血症会加重,低钾水平会降低心室颤动阈值。因此,尽管证据仍不完整,但MRFIT中伴有心电图异常的特殊干预男性中冠心病死亡率过高,可能是由于冠状动脉粥样硬化时左心室质量增加,以及利尿疗法依从性好导致低钾血症,并因应激诱导的循环儿茶酚胺增加而加重这两种因素共同作用所致。鉴于接受利尿疗法的患者数量众多,对这种可能性进行进一步评估很重要。